Cellular Immunotherapy to Inhibit PD-L1 for Oncology is under clinical development by ImmunityBio and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II drugs for Oropharyngeal Cancer have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cellular Immunotherapy to Inhibit PD-L1 for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cellular Immunotherapy to Inhibit PD-L1 for Oncology overview

Gene therapy is under development for the treatment of non small cell lung cancer, recurrent glioblastoma multiforme, gliosarcoma, recurrent head and neck squamous cell carcinoma (HNSCC), oral cavity cancer, oropharyngeal cancer, laryngeal cancer, hypopharyngeal cancer, nasal cavity and paranasal sinuses cancer and metastatic pancreatic cancer. The therapeutic candidate comprises tumor attacking natural killer cells (TANK) expressing chimeric antigen receptors (CAR-NK) targeting PD-L1. It is administered through parenteral and intravenous route as formulated as suspension. It was also under development for triple negative breast cancer, melanoma and renal cell carcinoma.

ImmunityBio overview

ImmunityBio, a subsidiary of NantWorks LLC, is a clinical-stage biotechnology company developing therapies for therapies for cancer and infectious diseases. The company product pipeline includes anktiva + BCG, anktiva + keytruda (pembrolizumab), aldox + anktiva + PD-L1 t-hank, anktiva + tri-ad5 vaccines, anktiva + bevacizumab + PD-L1 t-hank, anktiva + IBRX-042 vaccination, anktiva + M-ceNK and anktiva + CD19 t-haNK. ImmunityBio pipeline candidates treat bladder cancer, lung cancer, lynch syndrome, pancreatic cancer, glioblastoma, HPV, advanced Solid tumors, non-hodgkin lymphoma and HIV. The company operates in Italy, South Korea and the US. ImmunityBio is headquartered in San Diego, California, the US.

For a complete picture of Cellular Immunotherapy to Inhibit PD-L1 for Oncology’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.